Letter to the Editor: Bone health and denosumab treatment in autoimmune liver diseases: a possible involvement of physical activity.
In their pilot study, Arase et al.(1) assessed the efficacy and safety of treatment with denosumab for three years in postmenopausal osteoporotic women with autoimmune liver diseases such as primary biliary cholangitis and autoimmune hepatitis. Although there is debate, the authors' suggestion that denosumab can be used as a first-line osteoporosis drug(1) is supported by the Endocrine Society's clinical practice guideline for the pharmacological management of osteoporosis in postmenopausal women(2) . Here I would like to point out that physical activity might play a considerable role in both bone health and denosumab treatment in autoimmune liver diseases.